ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements with these filters
Fredun Pharmaceuticals allotted 3,61,599 equity shares following the conversion of 1,20,533 warrants. This allotment was executed at an issue price of Rs. 1,250 per warrant.
Fredun Pharmaceuticals acquired a 26% stake in ₹300 Crore-valued Goodman Vetcare, a dedicated pet pharmacy chain. Plans target PAN-India expansion with ~₹100 Cr revenue by FY31.
Fredun Pharmaceuticals allotted 2,71,200 equity shares following the conversion of 90,400 warrants. The board approved the issuance, raising Rs 11.3 Crore in total consideration.
Fredun Pharmaceuticals announced expansion of its Furlicks pet wellness range from 6 to 22 SKUs. The press release signals accelerated growth in the pet wellness segment.
Fredun Pharmaceuticals acquires pet-wellness brand Furlicks from USV and Wellbeing Nutrition. The deal marks strategic entry into India's pet-wellness market with plans to launch 44 new SKUs.
Fredun Pharmaceuticals launched PAWTALKS, a digital knowledge platform for pet and animal healthcare. Initially debuting on YouTube and Instagram, it connects veterinary experts with pet owners.
Fredun Pharmaceuticals delivered explosive Q1 FY27 growth with standalone income rising 90.44% YoY to INR 228.25 cr and PAT up 94.63% to INR 13.17 cr.
Fredun Pharmaceuticals submitted its Monitoring Agency Report for the quarter ended June 30, 2026, detailing the utilization of proceeds from its prior preferential allotment.
Fredun Pharmaceuticals reported Q1 FY27 total income of ₹228.25 Crore, a 90% YoY increase. Net profit rose 94.6% to ₹13.17 Crore during the same period.
Fredun Pharmaceuticals Ltd reported revenue from operations of ₹227.8 Cr (+90.8% YoY) and net profit of ₹13.1 Cr (+92.6% YoY) for Q1 FY27.
Fredun Pharmaceuticals Ltd has scheduled a board meeting on August 5, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.
Fredun Pharmaceuticals allotted 1.10 crore bonus shares in a 2:1 ratio. Post-issue paid-up capital increased to Rs 16.54 crore from Rs 5.51 crore.
Fredun Pharmaceuticals set July 16, 2026, as the record date for its 2:1 bonus issue. Shareholders will receive two new shares for every one held.